实验方法>
细胞技术>
前沿科技及其它>Liposomal Doxorubicin and nab-Paclitaxel: Nanoparticle Cancer Chemotherapy in Current Clinical Use
Liposomal Doxorubicin and nab-Paclitaxel: Nanoparticle Cancer Chemotherapy in Current Clinical Use
关键词: liposomal doxorubicin来源: 互联网
Liposomal doxorubicin and nab -paclitaxel are nanoparticle formulations of traditional cancer chemotherapy drugs which have ample clinical experience both pre- and post-nanoparticle modification. The alterations in pharmacokinetics, pharmacodynamics, efficacy, and toxicity compared with their parent compounds are instructive for future development of nanoparticle-based therapies. In this article we review the current status of these agents, emphasizing the alterations in clinical behavior resulting from the nanoparticle formulation of the parent compound.
推荐方法
- Immunological and Gene Therapy for Ovarian Cancer A Technical Overview
- Quality Assurance of Predictive Markers in Breast Cancer
- Tumor Vaccination with Cytokine-Encapsulated Microspheres
- UroVysion Multiprobe FISH in Urinary Cytology
- Lectin Array-Based Strategies for Identifying Metastasis-Associated Changes in Glycosylation
- In Vivo Xenograft Models of Breast Cancer Metastasis
- Flavonoid Compounds in the Prevention and Treatment of Prostate Cancer
- Calcium Phosphate Transfection of PC12 Cells 磷酸钙法转染PC12细胞
- 肾癌的survivin mRNA 基因序列
- The Androgen Receptor CAG Repeat and Prostate Cancer Risk